Regulation of ABC Transporters at the Blood–Brain Barrier

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 4, 2015, Pages 395-403

  Miller, D S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER;

ANIMAL; BIOSYNTHESIS; BLOOD BRAIN BARRIER; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; GENE EXPRESSION REGULATION; HUMANS;

EID: 85003050324     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.64     Document Type: Review

References (70)

1. Abbott, N.J. Blood-brain barrier structure and function and the chal-lenges for CNS drug delivery. J. Inherit. Metab. Dis. 36, 437–449 (2013).
2. Abbott, N.J., Ronnback, L. & Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53 (2006).
3. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R. & Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25 (2010).
4. Campos, C.R., Schroter, C., Wang, X. & Miller, D.S. ABC transporter function and regulation at the blood-spinal cord barrier. J. Cereb. Blood Flow Metab. 32, 1559–1566 (2012).
5. Cartwright, T.A., Campos, C.R., Cannon, R.E. & Miller, D.S. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J. Cereb. Blood Flow Metab. 33, 381–388 (2013).
6. Wang, X. et al. Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord bar-riers. J. Neurosci. 34, 8585–8593 (2014).
7. Moitra, K. & Dean, M. Evolution of ABC transporters by gene duplica-tion and their role in human disease. Biol. Chem. 392, 29–37 (2011).
8. Hartz, A.M. & Bauer, B. ABC transporters in the CNS — an inventory. Curr. Pharm. Biotechnol. 12, 656–673 (2011).
9. Sharom, F.J. Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein func-tion. Front. Oncol. 4, 41 (2014).
10. Chan, G.N., Hoque, M.T. & Bendayan, R. Role of nuclear receptors in the regulation of drug transporters in the brain. Trends Pharmacol. Sci. 34, 361–372 (2013).
11. Miller, D.S. & Cannon, R.E. Signaling pathways that regulate basal ABC transporter activity at the blood-brain barrier. Curr. Pharm. Des. 20, 1463–1471 (2014).
12. Zlokovic, B.V. The blood-brain barrier in health and chronic neurode-generative disorders. Neuron 57, 178–201 (2008).
13. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alz-heimer’s disease and other disorders. Nat. Rev. Neurosci. 12, 723– 738 (2011).
14. Abuznait, A.H. & Kaddoumi, A. Role of ABC transporters in the patho-genesis of Alzheimer’s disease. ACS Chem. Neurosci. 3, 820–831 (2012).
15. Dutheil, F. et al. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin. Drug Metab. Toxicol. 6, 1161–1174 (2010).
16. Mairinger, S., Erker, T., Muller, M. & Langer, O. PET and SPECT radio-tracers to assess function and expression of ABC transporters in vivo. Curr. Drug Metab. 12, 774–792 (2011).
17. Mittapalli, R.K., Manda, V.K., Bohn, K.A., Adkins, C.E. & Lockman, P.R. Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier. J. Neurosci. Methods 219, 188–295 (2013).
18. Uchida, Y. et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333–345 (2011).
19. Miller, D.S., Nobmann, S.N., Gutmann, H., Toeroek, M., Drewe, J. & Fricker, G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58, 1357–1367 (2000).
20. Shawahna, R., Decleves, X. & Scherrmann, J.M. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Curr. Drug Metab. 14, 120–136 (2013).
21. Lippmann, E.S., Al-Ahmad, A., Palecek, S.P. & Shusta, E.V. Modeling the blood-brain barrier using stem cell sources. Fluids Barriers CNS 10, 2 (2013).
22. Lippmann, E.S. et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30, 783– 791 (2012).
23. Bendayan, R., Lee, G. & Bendayan, M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech. 57, 365–380 (2002).
24. Hawkins, B.T., Rigor, R.R. & Miller, D.S. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J. Cereb. Blood Flow Metab. 30, 1593–1597 (2010).
25. McCaffrey, G. & Davis, T.P. Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. J. Invest. Med. 60, 1131–1140 (2012).
26. McCaffrey, G. et al. P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J. Neurochem. 122, 962–975 (2012).
27. Davis, T.P., Sanchez-Covarubias, L. & Tome, M.E. P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. Adv. Pharmacol. 71, 25–44 (2014).
28. Zhong, Y., Hennig, B. & Toborek, M. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells. J. Cereb. Blood Flow Metab. 30, 522–533 (2010).
29. Agarwal, S., Hartz, A.M., Elmquist, W.F. & Bauer, B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeep-ers team up. Curr. Pharm. Des. 17, 2793–2802 (2011).
30. Shawahna, R. et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8, 1332–1341 (2011).
31. Bauer, B. et al. In vivo activation of human pregnane X receptor tight-ens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70, 1212–1219 (2006).
32. Chan, G.N., Saldivia, V., Yang, Y., Pang, H., de Lannoy, I. & Bendayan, R. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study. J. Neurochem. 127, 342–352 (2013).
33. Wang, X., Sykes, D.B. & Miller, D.S. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol. Pharmacol. 78, 376–383 (2010).
34. Wang, X., Hawkins, B.T. & Miller, D.S. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J. 25, 644–652 (2011).
35. Durk, M.R. et al. 1alpha,25-dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J. Neurochem. 123, 944–953 (2012).
36. Bauer, B., Hartz, A.M., Fricker, G. & Miller, D.S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 66, 413–419 (2004).
37. Bauer, B., Hartz, A.M., Lucking, J.R., Yang, X., Pollack, G.M. & Miller, D.S. Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J. Cereb. Blood Flow Metab. 28, 1222–1234 (2008).
38. Narang, V.S. et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am. J. Physiol. Cell Physiol. 295, C440–450 (2008).
39. Roberts, D.J. & Goralski, K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin. Drug Metab. Toxicol. 4, 1245–1264 (2008).
40. Bauer, B., Hartz, A.M. & Miller, D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol. 71, 667–675 (2007).
41. Rigor, R.R., Hawkins, B.T. & Miller, D.S. Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J. Cereb. Blood Flow Metab. 30, 1373–1383 (2010).
42. Hartz, A.M., Bauer, B., Fricker, G. & Miller, D.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol. 69, 462–470 (2006).
43. Copple, I.M. The Keap1-Nrf2 cell defense pathway—a promising therapeutic target? Adv. Pharmacol. 63, 43–79 (2012).
44. Zhang, M., An, C., Gao, Y., Leak, R.K., Chen, J. & Zhang, F. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog. Neurobiol. 100, 30–47 (2013).
45. Cannon, R.E., Peart, J.C., Hawkins, B.T., Campos, C.R. & Miller, D.S. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc. Natl. Acad. Sci. U S A 109, 15930–15935 (2012).
46. Hawkins, B.T., Sykes, D.B. & Miller, D.S. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J. Neurosci. 30, 1417–1425 (2010).
47. Hartz, A.M., Bauer, B., Fricker, G. & Miller, D.S. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol. Pharma-col. 66, 387–394 (2004).
48. Miller, D.S. Sphingolipid signaling reduces basal P-glycoprotein activity in renal proximal tubule. J. Pharmacol. Exp. Ther. 348, 459–464 (2014).
49. Kalvass, J.C. et al. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based posi-tion. Clin. Pharmacol. Ther. 94, 80–94 (2013).
50. Nakanishi, T. & Ross, D.D. Breast cancer resistance protein (BCRP/ ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer 31, 73–99 (2012).
51. Hartz, A.M., Madole, E.K., Miller, D.S. & Bauer, B. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J. Pharmacol. Exp. Ther. 334, 467– 476 (2010).
52. Hartz, A.M., Mahringer, A., Miller, D.S. & Bauer, B. 17-beta-estradiol: a powerful modulator of blood-brain barrier BCRP activity. J. Cereb. Blood Flow Metab. 30, 1742–1755 (2010).
53. Prossnitz, E.R. & Barton, M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol. Cell. Endocrinol. 389, 71–83 (2014).
54. Mahringer, A. & Fricker, G. BCRP at the blood-brain barrier: genomic regulation by 17beta-estradiol. Mol. Pharm. 7, 1835–1847 (2010).
55. Scott, E.L. & Brann, D.W. Estrogen regulation of Dkk1 and Wnt/beta-catenin signaling in neurodegenerative disease. Brain Res. 1514, 63–74 (2013).
56. Harati, R., Benech, H., Villegier, A.S. & Mabondzo, A. P-glycoprotein, breast cancer resistance protein, Organic Anion Transporter 3, and Transporting Peptide 1a4 during blood-brain barrier maturation: involvement of Wnt/beta-catenin and endothelin-1 signaling. Mol. Pharm. 10, 1566–1580 (2013).
57. Pinzon-Daza, M.L. et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. J. Cereb. Blood Flow Metab. 34, 1258–1269 (2014).
58. Jablonski, M.R. et al. Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacore-sistance in ALS. Neurobiol. Dis. 47, 194–200 (2012).
59. Potschka, H. & Luna-Munguia, H. CNS transporters and drug delivery in epilepsy. Curr. Pharm. Des. 20, 1534–1542 (2014).
60. Vogelgesang, S. et al. Deposition of Alzheimer’s beta-amyloid is inver-sely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12, 535–541 (2002).
61. Vogelgesang, S. et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 1, 121–125 (2004).
62. Hartz, A.M., Miller, D.S. & Bauer, B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzhei-mer’s disease. Mol. Pharmacol. 77, 715–723 (2010).
63. ElAli, A. & Hermann, D.M. Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci. Signal. 3, ra72 (2010).
64. ElAli, A. & Hermann, D.M. Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abun-dance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells. Brain Pathol. 22, 175–187 (2012).
65. Loscher, W., Luna-Tortos, C., Romermann, K. & Fedrowitz, M. Do ATP-binding cassette transporters cause pharmacoresistance in epi-lepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des. 17, 2808–2828 (2011).
66. Potschka, H. Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. Adv. Drug Deliv. Rev. 64, 943–952 (2012).
67. Bauer, B., Hartz, A.M., Pekcec, A., Toellner, K., Miller, D.S. & Potschka, H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signal-ing. Mol. Pharmacol. 73, 1444–1453 (2008).
68. Pekcec, A. et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 330, 939–947 (2009).
69. Zibell, G. et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56, 849–855 (2009).
70. Avemary, J. et al. Dynamic regulation of P-glycoprotein in human brain capillaries. Mol. Pharm. 10, 3333–3341 (2013).